The massive dilution (~129%) combined with a $13M market cap and Nasdaq non-compliance signals severe financial distress. Monitor for potential reverse stock split or further capital raises. The warrant overhang (15.5M shares at $0.45) could pressure the stock if exercised.
Price Chart
Executive Summary
Actuate Therapeutics closed an $11.0M underwritten public offering of 30,985,900 common shares and 15,492,950 warrants (exercise price $0.45, 5-year term), with net proceeds of ~$9.96M for working capital. The offering represents ~129% dilution to pre-offering shares outstanding (24.0M) and was priced at a combined $0.71 per unit (two shares + one warrant). The company also faces Nasdaq MVLS non-compliance and has a $13M market cap.
Key Financial Metrics
Key Facts
- Priced $11.0M underwritten public offering of 30,985,900 common shares and 15,492,950 warrants at $0.71 per unit (two shares + one warrant).
- Net proceeds to company ~$9.96M after underwriting discounts and estimated expenses.
- Offering represents ~129% dilution to 24.0M pre-offering shares outstanding.
- Warrants exercisable at $0.45 per share, immediately exercisable, expiring in 5 years.
- Underwriter granted 45-day over-allotment option for up to 4,647,885 additional shares and 2,323,942 additional warrants.
- Underwriter's warrants issued at $0.44375 per share (125% of public offering price), subject to 180-day lock-up.
- Company faces Nasdaq MVLS non-compliance (market cap $13M).
- Offering closed on October 28, 2026.
Financial Impact
~$11.0M gross proceeds, ~$9.96M net proceeds; ~129% dilution to existing shareholders; potential additional $7.0M if warrants fully exercised on cash basis.
Risk Factors
- Extreme dilution (~129%) to existing shareholders from the offering.
- Nasdaq MVLS non-compliance risk could lead to delisting.
- Warrant overhang (15.5M shares at $0.45) may create selling pressure.
- Company has only $13M market cap and is a clinical-stage biopharma with no approved products.
- document contains text addressed to automated readers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-008143 |
| Document: actuate_ex0401.htm | 0001683168-26-008143 |
| Document: actuate_8k.htm | 0001683168-26-008143 |
| Document: actuate_ex9901.htm | 0001683168-26-008143 |
| Document: actuate_ex0501.htm | 0001683168-26-008143 |
| Document: 0001683168-26-008143-index-headers.html | 0001683168-26-008143 |
| Document: 0001683168-26-008143-index.html | 0001683168-26-008143 |
| Document: 0001683168-26-008143.txt | 0001683168-26-008143 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 today | SC 13G / 8-K | $0.3800 | awaiting T+5 | awaiting T+5 | $0.3351 (+11.82%) |
Oct 28, 2026 2d ago | 8-K | $0.3710 | awaiting T+5 | awaiting T+5 | $0.3351 (+9.68%) |
Oct 28, 2026 2d ago | 424B5 | $0.3833 | awaiting T+5 | awaiting T+5 | $0.3351 (+12.58%) |
Oct 27, 2026 3d ago | Press Release | $0.3995 | awaiting T+5 | awaiting T+5 | $0.3351 (+16.12%) |
Oct 27, 2026 3d ago | EFFECT | $0.3995 | awaiting T+5 | awaiting T+5 | $0.3351 (+16.12%) |
Oct 19, 2026 11d ago | S-1/A | $0.5990 $0.5279 | ▲ +11.87% | ▲ +11.72% | $0.3351 (+44.06%) |
Oct 14, 2026 16d ago | S-1/A | $0.4342 $0.5622 | ▼ −29.48% | ▼ −29.03% | $0.3351 (+22.82%) |
Oct 6, 2026 24d ago | S-1 | $0.7240 $0.4340 | ▲ +40.06% | ▲ +39.07% | $0.3351 (+53.72%) |
Aug 12, 2026 11w ago | Institutional Cluster | $0.9699 $1.06 | ▼ −9.29% | ▼ −9.73% | $0.3351 (+65.45%) |
Jun 9, 2026 20w ago | Press Release | $2.01 $2.05 | ▲ +1.99% | ▼ −0.42% | $0.3351 (−83.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers